List of Excipients in Branded Drug NEORAL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	NEORAL	cyclosporine	0078-0246	COCHINEAL
Novartis Pharmaceuticals Corporation	NEORAL	cyclosporine	0078-0246	CORN OIL
Novartis Pharmaceuticals Corporation	NEORAL	cyclosporine	0078-0246	FERROSOFERRIC OXIDE
Novartis Pharmaceuticals Corporation	NEORAL	cyclosporine	0078-0246	GELATIN
Novartis Pharmaceuticals Corporation	NEORAL	cyclosporine	0078-0246	GLYCERIN
Novartis Pharmaceuticals Corporation	NEORAL	cyclosporine	0078-0246	POLYOXYL 40 HYDROGENATED CASTOR OIL
Novartis Pharmaceuticals Corporation	NEORAL	cyclosporine	0078-0246	PROPYLENE GLYCOL

Neoral Excipient Strategy, Patent Position, Generic Competition, and Commercial Opportunities

Last updated: August 10, 2026

Neoral is the modified oral formulation of cyclosporine, marketed by Novartis. Its core commercial advantage is formulation-driven: a self-emulsifying microemulsion preconcentrate improves cyclosporine absorption and reduces the food and bile dependence associated with the earlier Sandimmune formulation. The principal opportunity is no longer basic compound protection. It is differentiated delivery, therapeutic drug monitoring, pediatric usability, excipient substitution, and lower-cost generic manufacture.

Neoral’s original regulatory exclusivity and formulation patents have expired. Generic cyclosporine modified products compete in the U.S., while formulation know-how remains commercially relevant because cyclosporine is a narrow-therapeutic-index immunosuppressant with clinically important exposure variability.

What is Neoral and how does its formulation work?

Neoral contains cyclosporine, a calcineurin inhibitor used primarily to prevent organ-transplant rejection and to treat selected autoimmune conditions. The product is available as modified-release or microemulsion-based oral dosage forms:

Product	Dosage form	Principal formulation concept	U.S. regulatory status
Neoral 25 mg	Soft gelatin capsule	Self-emulsifying microemulsion preconcentrate	FDA-approved NDA
Neoral 100 mg	Soft gelatin capsule	Self-emulsifying microemulsion preconcentrate	FDA-approved NDA
Neoral Oral Solution	Oral liquid	Same microemulsion-based delivery system	FDA-approved NDA

Neoral differs from Sandimmune because it forms a fine dispersion in gastrointestinal fluids without relying to the same extent on bile acids and dietary fat. The formulation improves the consistency of cyclosporine exposure, although patients still require therapeutic drug monitoring.

The product label identifies excipient classes that include:

• Corn oil mono-, di-, and triglycerides
• Polyoxyl 40 hydrogenated castor oil
• Propylene glycol
• Ethanol, particularly in the oral solution
• Alpha-tocopherol
• Gelatin-based soft capsule components
• Glycerin and sorbitol in the capsule shell
• Titanium dioxide and colorants, depending on dosage strength and market

The exact excipient profile can vary by dosage form and jurisdiction. The FDA labeling for Neoral and corresponding product information remain the controlling sources for composition and administration requirements.[1]

What excipient strategy protects Neoral?

Neoral’s excipient strategy is based on solubilization and spontaneous emulsification rather than conventional solid-dose dissolution enhancement.

Lipid phase

Corn oil mono-, di-, and triglycerides provide the primary lipid vehicle. These materials help dissolve cyclosporine and create an oil-in-water dispersion after exposure to gastrointestinal fluid.

The lipid system also affects:

• Droplet size
• Cyclosporine precipitation risk
• Absorption rate
• Food-effect sensitivity
• Physical stability
• Capsule-fill compatibility

A generic manufacturer cannot treat the lipid phase as a simple inert carrier. Small changes in fatty-acid composition, mono- and diglyceride ratio, or supplier grade can alter in vitro dispersion and in vivo exposure.

Surfactant phase

Polyoxyl 40 hydrogenated castor oil acts as a nonionic surfactant. It promotes spontaneous emulsification and maintains cyclosporine in a solubilized or finely dispersed state.

The surfactant level has a narrow optimization window. Excess surfactant can create tolerability, taste, viscosity, or capsule-shell compatibility problems. Insufficient surfactant can increase precipitation after dilution and produce higher pharmacokinetic variability.

Cosolvents and stabilizers

Propylene glycol and ethanol improve cyclosporine solubilization and support the liquid preconcentrate. Alpha-tocopherol functions as an antioxidant and helps protect the lipid system from oxidative degradation.

The formulation presents manufacturing and packaging constraints:

• Ethanol can affect fill-volume control and package permeability.
• Propylene glycol influences viscosity and dissolution.
• Lipid oxidation requires appropriate raw-material specifications and stability controls.
• Soft gelatin shells require compatibility testing with alcohols, surfactants, and lipid excipients.
• The oral solution requires controls for evaporation, crystallization, taste, and dose-measurement accuracy.

What formulations are protected by Neoral’s patent estate?

The historical patent estate focused on cyclosporine pharmaceutical compositions that use lipidic and surfactant-based systems to improve bioavailability and reduce absorption variability. The relevant protection was directed to formulation architecture, excipient combinations, and performance characteristics rather than to a new cyclosporine chemical entity.

Neoral’s original U.S. formulation patents have expired. The product therefore does not retain a meaningful period of market exclusivity based on the original formulation patents. Generic manufacturers have been able to develop cyclosporine modified products through the abbreviated new drug application pathway.

Protection category	Neoral position
Cyclosporine compound patent	Expired
Original microemulsion formulation patents	Expired
FDA exclusivity	Expired
Orange Book commercial barrier	No continuing basic exclusivity barrier
Trade secrets	Potentially relevant for process controls and raw-material specifications
New formulation patents	Available only for genuinely differentiated products
Regulatory exclusivity for a new version	Possible if the product satisfies FDA requirements

The most defensible current intellectual-property opportunities are new compositions, delivery systems, manufacturing processes, packaging systems, or clinically supported methods of use. Repackaging the same excipients at similar ratios would face weak patentability and freedom-to-operate prospects.

What is the Orange Book status of Neoral?

Neoral was approved by the FDA through new drug applications for modified cyclosporine capsules and oral solution. The original regulatory exclusivity period has ended, and cyclosporine modified products are available from generic manufacturers.

The Orange Book remains relevant for three reasons:

1. It identifies the reference listed drug used for generic approvals.
2. It records any patents or regulatory exclusivities associated with the listed product.
3. It supports analysis of Paragraph IV certifications and ANDA litigation.

For commercial planning, Neoral should be treated as an off-patent reference product. A new applicant’s principal barriers are formulation equivalence, bioequivalence, manufacturing validation, stability, and pharmacokinetic variability rather than expired composition patents.[2]

When did Neoral lose exclusivity?

Neoral lost effective market exclusivity after expiration of its original regulatory and formulation protections. The product has been commercially exposed to generic cyclosporine modified competition for many years.

The relevant timeline is:

Period	Event
Pre-1990s	Sandimmune establishes cyclosporine oral therapy but has significant absorption variability
1994	FDA approves Neoral modified cyclosporine formulations
Late 1990s to 2000s	Formulation and regulatory protection support branded positioning
2010s	Generic cyclosporine modified products expand in the U.S.
Current market	Competition centers on price, supply reliability, physician confidence, and pharmacokinetic consistency

Exact patent expiration dates depend on the patent, jurisdiction, patent-term adjustments, and any applicable pediatric or regulatory extensions. The commercial conclusion is unchanged: the original Neoral formulation estate no longer blocks generic entry.

Which companies are challenging Neoral?

Neoral has faced generic competition rather than a current biosimilar challenge. Cyclosporine is a chemically synthesized small molecule, so biosimilar legislation does not apply.

Generic competition has included manufacturers of cyclosporine modified capsules and oral solutions approved through ANDAs or other national generic pathways. Depending on the jurisdiction, suppliers may include large generic companies, specialty pharmaceutical manufacturers, and regional drug makers.

The competitive issues are:

• Demonstration of bioequivalence to the reference product
• Control of peak and total cyclosporine exposure
• Consistency across fed and fasted conditions
• Capsule and oral-solution stability
• Reliable supply of specialized lipid excipients
• Physician acceptance in transplant medicine
• Pharmacist substitution rules
• Product-switching policies for narrow-therapeutic-index drugs

Cyclosporine modified products are not interchangeable with Sandimmune merely because both contain cyclosporine. The modified and nonmodified formulations have different absorption profiles and should not be substituted without clinical oversight.[1]

How strong is the Neoral patent estate?

The expired patent estate was technically meaningful but commercially weak as a present-day blocking position.

Patent-estate factor	Assessment
Compound protection	None remaining
Core formulation protection	Expired
Regulatory exclusivity	Expired
Manufacturing know-how	Moderate potential value
New-product blocking position	Limited
Generic entry barrier	Formulation and bioequivalence execution
Litigation leverage	Low for the original product
Differentiation potential	Moderate in new delivery formats

A new entrant could obtain patents around a materially different cyclosporine formulation, including:

• Supersaturating lipid systems
• Amorphous or nanocrystalline cyclosporine
• Taste-masked oral liquids
• Pediatric dispersible granules
• Unit-dose sachets
• Alcohol-free microemulsion systems
• Reduced-surfactant formulations
• Long-term refrigerated or room-temperature stable formulations
• Drug-device combinations for accurate liquid dosing
• Formulations optimized for enteral feeding tubes

Patent strength would depend on comparative data. Useful evidence would include droplet-size distributions, precipitation resistance, dissolution, pharmacokinetics, food-effect data, storage stability, and clinically relevant exposure variability.

What commercial opportunities exist in Neoral excipients?

The strongest opportunities are in improved patient usability and supply-chain resilience.

Alcohol-free oral solution

A non-ethanolic oral solution could address taste, pediatric use, alcohol-sensitive populations, and packaging concerns. The formulation would need to maintain cyclosporine solubility and prevent precipitation after dilution.

Potential claims could cover:

• A specific lipid-surfactant-cosolvent ratio
• Ethanol-free composition
• Improved storage stability
• Reduced precipitation after dilution
• Improved palatability
• Compatibility with enteral administration

Pediatric formulation

Pediatric transplant patients may benefit from a low-volume, accurately measurable formulation. Opportunities include:

• Lower-strength capsules
• Dispersible granules
• Oral films
• Metered liquid dispensers
• Flavored oral solutions
• Unit-dose delivery systems

The primary commercial value is adherence and dosing precision. A product that reduces dose-measurement errors could compete even in a generic market.

Enteral-tube compatibility

Transplant patients may require feeding tubes during hospitalization or recovery. A formulation designed for tube delivery could reduce clogging, adsorption, dose loss, and handling variability.

A differentiated product could claim:

• Defined tube materials
• Administration dilution
• Flush volume
• Recovery percentage
• Stability after preparation
• Compatibility with common enteral feeds

Reduced-excipient formulation

Polyoxyl 40 hydrogenated castor oil and ethanol can create tolerability and handling concerns. A lower-surfactant or surfactant-free system would have commercial relevance if it preserves bioavailability and stability.

Possible enabling technologies include:

• Medium-chain lipid systems
• Self-emulsifying drug delivery systems
• Nanostructured lipid carriers
• Amorphous solid dispersions
• Cyclodextrin or alternative solubilizer systems

Softgel manufacturing and contract supply

Neoral-like products require specialized softgel encapsulation, liquid-fill control, and lipid-excipient handling. Contract manufacturers with validated equipment and experience with volatile cosolvents can create value through:

• Private-label generic supply
• Regional licensing
• Dual-source manufacturing
• Technology transfer
• Finished-dose supply to transplant pharmacies

What manufacturing and intellectual-property barriers affect generic entry?

Generic entry is technically feasible but not equivalent to ordinary immediate-release capsule development.

Key barriers include:

1. Achieving consistent self-emulsification after capsule rupture.
2. Matching the reference product’s pharmacokinetic profile.
3. Controlling cyclosporine precipitation during dilution.
4. Managing oxidation of lipid excipients.
5. Preventing capsule-shell interaction.
6. Maintaining fill-weight accuracy at commercial scale.
7. Establishing stability under shipping and temperature excursions.
8. Validating oral-solution dosing devices.
9. Securing qualified suppliers for specialized excipients.
10. Managing therapeutic substitution in transplant patients.

Cyclosporine’s narrow therapeutic index increases the commercial consequences of small formulation differences. FDA guidance treats narrow-therapeutic-index products as requiring careful bioequivalence evaluation, and sponsors should expect scrutiny of exposure variability and study design.[3]

What patent litigation and Paragraph IV risks affect Neoral?

The main Paragraph IV risk period occurred when generic sponsors first challenged or designed around the original Neoral formulation protections. Those protections have expired, so current market entry is generally driven by abbreviated approval, manufacturing readiness, and commercial contracting.

A new entrant creating an improved cyclosporine formulation could generate new litigation risk if it seeks to block later competitors. The likely dispute areas would be:

• Lipid and surfactant ratios
• Particle or droplet size
• Crystallization inhibition
• Alcohol-free systems
• Dose-delivery devices
• Stability claims
• Process patents
• Treatment methods tied to pharmacokinetic control

A patent directed only to the use of familiar excipients in predictable proportions would face validity risks under obviousness law. Stronger claims would connect composition to an unexpected technical effect, such as lower food-effect variability or substantially improved stability.

How does Neoral compare with Sandimmune and generic cyclosporine?

Attribute	Neoral	Sandimmune	Generic cyclosporine modified
Formulation	Microemulsion or modified lipid system	Older nonmodified formulation	Designed to match modified reference
Absorption consistency	Generally improved	More food and bile dependent	Must demonstrate bioequivalence
Dosage forms	Softgel capsules and oral solution	Capsules, oral solution, injection in historical markets	Primarily capsules; oral solution availability varies
Patent position	Expired	Expired	Competes commercially
Clinical substitution	Requires attention to product type	Not interchangeable with modified products	Product-specific
Main competitive lever	Brand familiarity and supply	Limited modern differentiation	Price and supply reliability
New opportunity	Pediatric, alcohol-free, tube-compatible products	Limited	Differentiated formulation and manufacturing

Neoral remains the relevant reference concept for modified cyclosporine delivery. Sandimmune is a separate formulation category, not a direct substitute.

What revenue exposure and market opportunities exist?

The original brand has limited pricing power because cyclosporine modified products are genericized. Revenue opportunities are more attractive in specialized niches than in an undifferentiated capsule.

The highest-value commercial segments are:

Opportunity	Commercial attractiveness	Primary value driver
Standard generic capsules	Moderate	Manufacturing cost and supply
Generic oral solution	Moderate to high	Fewer competitors and dosing complexity
Pediatric formulation	High	Adherence and dosing precision
Alcohol-free liquid	Moderate to high	Patient acceptability and differentiation
Enteral-tube product	High in institutional settings	Administration reliability
Excipient supply	Moderate	Qualified-source status and consistency
New microemulsion platform	High but development-intensive	Reusable delivery technology
Combination adherence product	Moderate	Patient support and refill persistence

The most defensible strategy is a platform approach: develop a cyclosporine formulation technology that can support multiple strengths, pediatric versions, oral liquids, and other poorly soluble immunosuppressants.

Key Takeaways

• Neoral is a modified cyclosporine formulation built around a lipid-based self-emulsifying delivery system.
• Its original compound, formulation, and regulatory protections have expired.
• The principal formulation value lies in excipient architecture, manufacturing control, and pharmacokinetic consistency.
• Generic entry is established, but narrow-therapeutic-index requirements preserve technical barriers.
• Biosimilar risk does not apply because cyclosporine is a small-molecule drug.
• The strongest commercial opportunities are alcohol-free liquids, pediatric products, enteral-tube formulations, accurate dosing devices, and differentiated lipid systems.
• New patents require composition, process, or performance claims supported by comparative technical data.
• The original Neoral patent estate has limited current blocking power, while manufacturing know-how and formulation execution remain commercially relevant.

FAQs

Can Neoral capsules be substituted with Sandimmune?

No. Neoral is a modified cyclosporine formulation, while Sandimmune is a nonmodified formulation. Substitution can change cyclosporine exposure and requires clinical management.

Is Neoral still protected by active U.S. formulation patents?

The original Neoral formulation protections have expired. New patents could cover later-developed formulations, devices, or manufacturing processes, but those would not restore exclusivity to the original product.

Which excipient is most important in Neoral?

The formulation depends on the combined action of the lipid vehicle and surfactant system. Corn oil mono-, di-, and triglycerides provide the lipid phase, while polyoxyl 40 hydrogenated castor oil supports self-emulsification.

Can an alcohol-free Neoral formulation be patented?

Yes, if the composition is novel and produces a non-obvious technical result, such as improved stability, reduced precipitation, better palatability, or comparable exposure without ethanol.

Why is cyclosporine generic development more difficult than ordinary capsule development?

Cyclosporine has a narrow therapeutic index and highly formulation-dependent absorption. Generic developers must control self-emulsification, precipitation, food effects, and pharmacokinetic variability in addition to ordinary quality and stability requirements.

References

1. Novartis Pharmaceuticals Corporation. (2023). Neoral (cyclosporine modified) capsules and oral solution prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov

3. U.S. Food and Drug Administration. (2012). Bioequivalence recommendations for cyclosporine. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2018). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

5. United States Pharmacopeia. (2024). General chapter <1081>: Therapeutic drug monitoring. United States Pharmacopeial Convention.